Results 141 to 150 of about 5,644,882 (290)

VALUES OF SCAN RESEARCH [PDF]

open access: yes
Research Methods/ Statistical Methods,
Capps, Oral, Jr.
core   +1 more source

Sevgili Oktay Rifat [PDF]

open access: yes, 1988
Taha Toros Arşivi, Dosya No: 135-Oktay Rifat-Samih Horozcu. Not: Gazetenin "Esintiler" köşesinde yayımlanmıştır.Unutma İstanbul projesi İstanbul Kalkınma Ajansı'nın 2016 yılı "Yenilikçi ve Yaratıcı İstanbul Mali Destek Programı" kapsamında ...
Oral, Zeynep
core  

Preferences for post‐traumatic osteoarthritis prevention strategies in individuals with anterior cruciate ligament injury

open access: yesArthritis Care &Research, Accepted Article.
Objectives There is growing interest in evaluating new strategies to delay or prevent post‐traumatic osteoarthritis (PTOA) in individuals who have sustained anterior cruciate ligament (ACL) injury. This study sought to determine characteristics of potential treatments that are acceptable to patients with ACL injury.
Kevin Kennedy   +9 more
wiley   +1 more source

EMPIRICAL INVESTIGATION OF THE IMPACT OF THE 2007 RECALL ON THE DEMAND FOR PEANUT BUTTER BRANDS [PDF]

open access: yes
The US Food and Drug Administration confirmed in February 2007 that a major foodborne illness outbreak was caused by two peanut butter brands, Peter Pan and Great Value, manufactured by ConAgra Foods Inc. at its Sylvester, Georgia, processing plant. As a
Bakhtavoryan, Rafael   +2 more
core   +1 more source

Tanıtım ve Türk turizminde Karagöz [PDF]

open access: yes, 1989
Taha Toros Arşivi, Dosya No: 176-Karagöz Sanatkarlarıİstanbul Kalkınma Ajansı (TR10/14/YEN/0033) İstanbul Development Agency (TR10/14/YEN ...
Oral, Ünver
core  

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan   +7 more
wiley   +1 more source

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

open access: yesArthritis Care &Research, EarlyView.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer   +5 more
wiley   +1 more source

Testing a Personalized Approach to Chronic Low Back Pain: A Randomized Controlled Trial in Older Veterans

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to test the efficacy of personalized treatment of older veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABCs) as compared with usual care (UC). Methods Two hundred ninety‐nine veterans aged 65 to 89 with CLBP from three Veterans Affairs (VA) medical centers underwent baseline testing, randomization to ABC ...
Debra K. Weiner   +9 more
wiley   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy